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Cancer immunotherapy has now finally made its way and entered a new era, after decades of 
intensive searching of a cure for the incurable. Current attentions are particularly drawn by the 
very promising outcomes from a series of experimental and clinical studies recently concluded 
[1], having tested and verified the “Immune Checkpoint Blockade” working hypothesis initially 
proposed by Dr. James Allison nearly 20 years ago [2]. The next central question is about how to 
extend or maximize the therapeutic and survival benefits for greater numbers of patients, and of 
different cancer types. This may be achieved by further identifications of new target checkpoint 
inhibitors, emphasizing more on the tumor-specific antigenic signals, and through combination 
with the therapeutic vaccination approach in particular. Here, by joining in the discussion, I intend 
to start with direct reference to various basic yet constantly evolving concepts based on which 
vaccination against neoplasm has been developed along, and now progressing towards.
The Concept of Vaccination
Vaccination against illness is conceptually not just an old but ancient medical practice in human 
history [3]. The significance and great potential attached with were however not widely or formally 
appreciated until much later, starting late 18th Century after Dr. Edward Jenner in particular had 
proven its protective effects against Smallpox infection. He demonstrated successfully then (1796), 
and in a more scientific way we now understand, the prevention of this highly contagious Smallpox 
(Variola) human disease by inoculation of individuals alternatively, and more safely, with its bovine 
analog which caused Cowpox (Vaccinia). In particular, this was done even long before virus as a 
disease causing infectious agent was first identified a century later (Dmitri Iwanowski, 1892). Such a 
conceptual advance is undoubtedly one of the greatest medical discoveries in human history. It has 
led to the eradication of this fatal disease, officially announced by the World Health Organization 
(WHO) in May 1980. The very concept has since been adopted and widely applied thereafter against 
different types of infections too, preventing illness and death of millions each year on the planet. 
Importantly, the Jenner’s discovery has laid down the very basis of Immunology subject-wise. 
His idea of vaccination has later also been further extended immunologically for the prevention and 
treatment of other types of diseases too, including cancers.
Evidence of Natural Immunity against Cancer
There has been strong evidence indicating that the host immune system is involved in fighting 
against cancers. Simply based on clinical or pre-mortem data versus postmortem findings, cancer 
occurrence rates are often found to be greater than those clinically diagnosed [4]. This might 
of course depend on the ways and sensitivity of the tests used but, on the other hand, it could 
alternatively also suggest that tumors might simply ‘come’ and ‘go’ without being noticed, hinting the 
existence of certain mechanisms responsible for their elimination. Indeed, spontaneous regression 
of cancers has been observed clinically and experimentally too, often with evidence of immune 
cells infiltrating and/or surrounding the tumors [5,6]. In support of these notions, mice lacking an 
intact immune system have been found to be more susceptible to carcinogen-induced cancers [7,8]. 
These together with the facts that cancer occurrence rates are also evidently higher in patients with 
immunodeficient conditions such as the acquired immunodeficiency syndrome (AIDS) [9], and in 
individuals at certain stages when their immune capacity can be physiologically low (e.g. neonatal or 
old age), point to a crucial role of the immune system in controlling cancer development.
Moreover, on an oncological basis, tumors by definition are caused by mutations due to genetic 
defects and/or environmental triggering of various types including chemical carcinogens, irradiation, 
and many that can be virus-induced (oncoviruses, e.g. HBV, HCV, EBV, HPV…) too. Whichever 
of these causes, from an immunological point of view, the mutations may potentially give rise to 
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the so-called ‘neo-epitopes’ as part of the Tumor-Specific Antigen 
(TSA). To which, the host immune system may respond specifically 
against, or directly to the viral-related gene products (e.g. due to virus 
insertions), i.e. for their ‘foreignness’ nature [10,11]. Some of the 
mutations may also cause downstream aberrant expression of certain 
normal genes leading to over-expression of their encoded cellular 
proteins (Tumor Associated Antigens, TAA), i.e. at levels above 
a threshold, but otherwise below which such immune responses 
would not be triggered. A phenomenon known as the Graft-versus-
Leukemia (GVL) anti-tumor effect, observed in leukemia patients 
following allogenic bone marrow transplantation, has been used by 
immunologists as good evidence to argue for the existence of host 
immune capacity against cancer. It is believed that the recognition 
of TSA/TAA expressed on the leukemic mutants (blasts) by the 
immunocompetent allogenic donor T cells can be directly responsible 
for their subsequent elimination [12].
In brief, there is clear evidence that the immune system can 
protect the host from cancer development. It does so by constantly 
monitoring and trying to eliminate any potential cancerous cells or 
neoplastic components in the body, a mechanism explained by the 
Cancer Immunosurveillance hypothesis [13]. The establishment of 
such a theory has however also taken a long time to evolve from its 
initial concept/idea to the present form [14,15].
Cancer Immunosurveillance, Immunoediting & Vice 
Versa
The concept of cancer immunosurveillance, based on the initial 
ideas of Drs. William Coley (1891) and Paul Ehrlich (1909) more 
than a century ago, was proposed, tested and later theorized by Drs. 
Macfarlane Burnet and Lewis Thomas in the late 1950s [13,14,16-18]. 
Its original concept predicted that the immune system could have 
a protective (positive) role against cancers, by ways to block their 
initiation and development [17]. Cancer formation was therefore 
considered as a failure of the immune system in this regard. This 
has however been wondered and queried in many ways since. An 
immediate question was then how tumors could still manage to 
‘sneak through’ escaping from the host immunosurveillance in the 
patients. There had been a series of early attempts though with many 
conflicting findings, trying to prove for the existence of TSA/TAAs, 
and to figure out the identity of immune cell types or molecules 
potentially responsible for cancer rejection. Many were then intrigued 
by the fact that tumors formed in the absence of an intact immune 
system were in general more immunogenic than those generated 
in the immunocompetent hosts [7,8]. These findings suggested 
that the neoplastic cells could have been differentially imprinted, 
depending on the immunological microenvironment they were in. 
As a refinement of the cancer immunosurveillance theory, another 
layer or layers of interpretations were added to embrace the so-called 
cancer immunoediting hypothesis. In the revised theory, a cancer 
immunoediting process proceeding sequentially through different 
stages, namely “Elimination”, “Equilibrium” and “Escape” (3-Es), was 
postulated [18,19]. According to which, as a result of immunoediting, 
certain selected cancer cells (variants) could acquire an ability of 
resistance to their elimination being a real cord of tumor formation. It 
thus has started acknowledging both of the host-protecting (positive) 
and tumor-sculpting (negative) actions of the immune system on 
tumor development [19].
Subsequent findings suggest that there may be even more 
complex interactions between the host immune system and the 
tumors, mutually shaping each other, through which the cancer cells 
could actively suppress the host immune system too. There is now 
strong evidence indicating that tumors can interact directly with 
host immune cells in return to block their functions, e.g. through the 
expression of various immunosuppressive molecules or cytokines 
[20-27]. It is also highly likely that, as a result of immunoediting, the 
cancer cells may acquire an enhanced such capacities to do so thus 
facilitating better their immune escape. Indeed, many TSA/TAA-
specific T and B cell clones have been identified in cancer patients, 
but most of them were found in an unresponsive or anergized state 
[28,29]. These have prompted further questions since, as to how these 
TSA/TAA-specific lymphocytes are tolerized or suppressed, what are 
the intrinsic cellular and molecular mechanisms involved and, most 
importantly, whether and how these anergized lymphocyte clones 
can be alternatively switched on or redirected to enhance their anti-
tumor potential [3,21,30].
Vaccination against Cancer - The Active Immunological 
Approach
Prompted by his early idea linking the host immune responses 
to bacterial infections with those against cancers, the bone surgeon 
William Coley was again the first (1891) to have proposed and shown 
that post-surgical bacterial infections, or injection of killed bacteria 
(Coley’s toxin or Coley’s ‘vaccine’), might help in some way to boost 
the host immunity against tumors [14]. Such a boosting, though 
seemingly in a rather non-specific way, can be well explained and 
experimentally verified by the widely observed additional potentiating 
effects of the so-called Complete Freund’s Adjuvant (CFA). CFA 
contains inactivated mycobacterial components, unlike its incomplete 
counterpart (IFA, without the mycobacterial components), used in 
a conventional vaccination procedure against infections. Indeed, 
the phenomenon of spontaneous cancer regression has also been 
observed often concomitant with some kind of infection too [5]. 
Although there had been concerns about potential adverse effects of 
Coley’s approach, his idea at the time did make conceptually an early 
start of cancer immunotherapy subject-wise. Ever since, a variety 
of other ideas and approaches have been proposed and tested in 
different experimental models as well as clinical trials, all with a sole 
aim to enhance host immunity against the nascent mutant targets. 
The main experimental or treatment modalities of cancer 
immunotherapy include the use of non-specific immune enhancers, 
e.g. immunogenic cytokines (e.g. IL-2, IFN-α) or molecules (e.g. 
antibodies) [31,32]; adoptive transfer of ex vivo expanded/activated 
autologous or allogenic T or Natural Killer (NK) cells [33-35].; and 
the development of specific cancer vaccines [30,36-38]. By harnessing 
the two key features of the adaptive immunity, i.e. antigen specificity 
and immunological memory, vaccination against cancer is by 
nature a more active or positive immunological approach. It aims 
to establish a long lasting and self-propagating immunity in the host 
and, importantly, with specificity hence better strength against those 
cancerous mutant cells. Different cancer vaccines of therapeutic 
and prophylactic types have been developed and tested (for details, 
please see a recent review by LH Butterfield [38]). These include the 
conventional vaccination regiments by injecting tumor antigens 
together with certain immune enhancers or adjuvants, DNA vaccines 
encoding tumor-specific epitopes pre-identified, and even the use of 
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live cells such as Dendritic Cells (DC) as an immunogenic cell vector 
for tumor antigen delivery.
The original idea of DC-based tumor vaccine in particular was 
prompted by the understanding that DC could be a potent Antigen 
Presenting Cell (APC) essential for T-cell activation [30]. For their 
uniquely combined immunobiological properties, DC are believed to 
be the only cell type capable of activating naïve T cells in vivo, crucial 
therefore in the initiation of the adaptive anti-tumor immunity [39]. 
These, together with the fact that DC could be generated in vitro in 
large numbers  [40-42] and readily loaded with either defined or even 
un-defined tumor antigens (e.g. tumor lysates)  [43], have led to the 
attractive concept of using DC as an immunogenic cell vector for 
cancer vaccine delivery [30,44-48]. Despite some favorable findings 
mainly from studies in experimental models, however, clinical 
applications have thus far been limited by a lack of achievable general 
efficacy and consistency. Outcomes from many clinical trials had not 
been met with initial expectations [49,50]. The main obstacle identified 
among others appears to be the highly immunosuppressive tumor 
microenvironment, under which DC can be switched phenotypically 
and functionally to induce tolerance instead of immunity [21].
Nevertheless, some promising results from several recently 
concluded clinical trials of Sipuleucel-T (Provenge), the first and 
only human DC-based cancer vaccine approved (2010) by the 
American Food and Drug Administration (FDA) for the treatment 
of asymptomatic/minimally symptomatic metastatic castration-
resistant prostate cancer (mCRPC) [51], have been demonstrated 
[52,53]. In these studies, clinical improvement in terms of the 
overall and/or prostate cancer-specific survival rates appeared to be 
associated with measurable antibody responses against certain non-
targeted (secondary) tumor antigens [52], and a transient increase 
of circulating eosinophils [53], in the patients. Prophylactic vaccines 
(Gardasil, Cervarix) against the oncogenic human papillomavirus 
have also recently been shown to be effective in preventing cervical 
[37,54]. With recent rapid advances in our understanding of the 
cellular and molecular mechanisms underlying tumor immune 
escape and beyond, the field of cancer vaccination is now expected to 
get a real boost soon.
Insights from Studies of Autoimmune Mechanisms - 
Immunity against ‘Self’ & the ‘Altered-Self’
Recent findings from studies of the mechanisms underlying 
autoimmunity, and more importantly, the mechanisms protecting 
against it, have offered some new insights for our understanding of 
cancer immune escape. 
Chronic or persistent autoimmune-like inflammatory conditions 
are evidently associated with tumor development. These may 
trigger neoplastic transformation and through the production of 
inflammatory mediators to promote cancer cell survival, proliferation 
and invasion [55,56]. The important question is however about their 
true intrinsic causal relationship. To prevent autoimmune attack, it 
is believed that the immune system needs to be ‘educated’ early in 
life (thymic selection) [57,58], and continuously through adulthood 
(peripheral tolerance mechanisms) [59]. During which, cells of 
the adaptive immune system especially T cells with potential self-
reactivity are largely removed or immunologically “silenced”. As 
mentioned above, tumors are by nature clones of mutated cells arisen 
from the body’s own tissues, to which the host immune system is 
largely tolerized otherwise. Although those mutations occurred in 
cancers may give rise to TSAs and TAAs, most of these newly derived 
or “altered-self” neo-antigens are likely to remain low immunogenic 
when presented to the host immune system [20]. The ongoing 
inflammatory condition may therefore reflect the desperate attempts 
of the host immune system to mount anti-tumor responses, being a 
consequence of the continuous yet largely futile triggering by those 
poorly immunogenic TSA/TAAs. These may then in return trigger 
further self-protective mechanisms, i.e. anti-inflammatory responses 
to limit tissue damage. As the result of such a negative feedback 
loop, an excessive production/expression of anti-inflammatory or 
immunosuppressive cytokines (e.g. IL-10, TGF-β) or molecules (e.g. 
PD-1/PD-1L), followed by the exhaustion of the immune effector 
cells, may instead lower the ability of the host immune system to 
mount specific anti-tumor responses. It has also been shown that 
chronic T cell attack on a tumor could silence the expression of certain 
TSA through epigenetic alterations [60], a process which influences 
similarly the development and regulation of autoimmunity too [61]. 
Understandably, cancer immune escape could thus be related to, and 
well explained by, the immunological mechanisms underlying self-
tolerance. In other words, as an original member of ‘Self’, tumors (the 
‘altered-Self’) can still benefit from, and be largely protected by, these 
self-tolerance mechanisms. 
Through a better understanding of the detailed cellular 
and molecular mechanisms underlying self-tolerance versus 
autoimmunity [62,63], we have gained some critical insights into 
the mechanisms of cancer immune escape [64]. Most importantly, it 
has also helped to identify better ways to break more effectively the 
vicious circle involved in the processes of Cancer Initiation, Chronic 
Inflammation and Cancer Immuno-escape (Ci-Ci-Ci). Among them, 
IL-10 in particular has been identified as one of the crucial factors 
limiting the efficacy of vaccination against tumors [21,64]. By blocking 
selectively the IL-10-IL-10R signaling pathway, greatly enhanced 
vaccine efficacy has now been clearly demonstrated in various animal 
models of liver, skin and lung cancers [21,64,65]. Moreover, findings 
from these conceptually related studies have also helped to explain 
why the most effective way to enhance the efficacy of cancer vaccines 
is by targeting the negative arm of immune regulation, i.e. by tipping 
the immunological ‘balance’ but in a positive way.
Recent Breakthroughs in Cancer Immunotherapy 
- The Concept of Immune Checkpoint Blockade & 
Further Beyond
Immunology is a subject best coinciding conceptually with the 
ancient Chinese philosophy of ‘Yin’ and ‘Yang’. The so-called ‘Yin-
Yang’ balancing act is indeed well reflected in every part of the 
immune system, of both the innate and the adaptive arms [66,67]. 
T cells, which are crucial for anti-tumor responses, require two 
essential types of signals for their activation. One is delivered through 
antigen-specific stimulation (Signal 1), and the other refers to a group 
of antigen-independent but essential co-stimulatory signals (Signal 
2), both of which can be provided by the APC they interact with. 
Ligation of CD28 on T cells by its ligand (B7) on the APC such as 
DC has been shown to provide such essential co-stimulatory signals 
required for the activation of T cells, of naïve T cells in particular. It 
has subsequently also revealed that the so-called Signal 2 could be 
of two types too, which determined the outcome of T cells either in 
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a positive or negative way depending on their mutual balance. The 
Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) molecule (CD152) 
is one of the key negative regulators identified, and found to be 
expressed on T cells following activation [68]. CD28 and CTLA-4 
are both members of the immunoglobulin super family, and share 
high (75%) nucleotide sequence homology. CTLA-4 can also bind 
with the same ligands (B7-1, CD80; B7-2, CD86) as CD28, but with a 
much higher affinity (10-40 folds). Upon CTLA-4 ligation, in contrast 
to that of CD28 however, the T cell will receive an inhibitory signal 
instead, for its inactivation [68]. Such a balancing act, as a necessary 
‘brake’ to prevent overt immune responses, has been shown to be 
crucial in protecting the host from self-destructive autoimmune, 
inflammatory as well as lymphoproliferative diseases [69,70].
Prompted by the cellular and molecular understanding of the 
‘Yin-Yang’ balance involved in T cell co-stimulation and inhibition 
[66], Dr. Allison came up with his original hypothesis of Immune 
Checkpoint Blockade, and started testing its implications in cancer 
immunotherapy. This has subsequently led to the identification 
of CTLA-4 being ‘hijacked’ by cancer cells and involved in the 
immunological mechanisms underlying tumor evasion. In 1996, the 
group led by Dr. Allison demonstrated for the first time that the use 
of antibodies to block CTLA-4 could boost anti-tumor immunity in 
animal models [2]. They showed that injection of the CTLA-4 blocking 
antibodies alone could significantly enhance the host immunity 
against murine colon carcinoma and fibrosacoma, including the pre-
established tumors of either B7-positive or B7-negative genotype 
[2]. By combining the use of a tumor cell vaccine expressing a 
pro-inflammatory cytokine, Granulocyte/Macrophage Colony-
Stimulating Factor (GM-CSF), they demonstrated subsequently 
how a further enhancement of such immunity, mediated largely by 
cytotoxic T cell killing, could be achieved in an otherwise highly 
tumorigenic but poorly immunogenic melanoma mouse model [71]. 
Most importantly, these findings from animal studies have later led 
to the development of the monoclonal antibody (ipilimumab) against 
human CTLA-4 and tested in a series of clinical trials. Among them, 
the first randomized Phase III clinical trial using ipilimumab was 
published in 2010 [72], which showed promising overall survival 
benefits and durable responses though in a subgroup (20%) of patients 
with metastatic melanoma. This together with further verification 
from other related studies has led to its approval by FDA in 2011. 
Under the very concept, and again based on preclinical findings in 
animal models, several other key molecular switches including the 
programmed cell death protein 1 (PD-1) on activated T cells, and 
the PD-1 ligands (PD-L1, CD274/PD-H1; PD-L2, CD273/PD-DC) 
on many cell types including tumor cells, have also been identified. 
The ligation of PD-1 can limit the functions of T cells involved in 
the mechanisms underlying self-tolerance/autoimmunity versus 
host immunity against cancers [73-76]. Thereafter, various human 
or humanized antibodies against PD-1 (nivolumab/BMS936558, 
pembroluzimab/lambrolizumab) and PD-L1 (BMS935559, 
MPDL3280A) have been designed, and developed for targeting the 
PD-1/PD-L1 axis/pathway. The immune enhancing effects of these 
antibodies have recently been evaluated in a series clinical trials (see 
review in [77]), which showed promising clinical responses (tumor 
regression) though again of different degrees, in multiple human 
tumor types including advanced melanoma, prostate, colorectal, 
renal and non-small-cell lung cancers [78-81]. 
These clinical verifications of the Immune Checkpoint Blockade 
working hypothesis have now clearly opened up a new horizon in 
the field of cancer immunotherapy, offering hope for many with a 
disease otherwise classified as irremediable by conventional therapies 
[23]. In celebrating these achievements, by the end of 2013, the 
Science magazine selected this very topic and branded it as the “Top 
Breakthrough of the Year 2013” [1]. Since then, more and more 
reports have been filed with positive results supporting the concept, 
and the enthusiasm has been running higher each day. On the other 
hand, however, this therapeutic approach so far in general appears to 
have benefited only a subgroup or fraction of patients, and of those 
with long term remission in particular. Current attention is now 
focused on how to broaden the clinical benefit for greater number 
of patients, and of different cancer types. In order to achieve this 
further, a number of strategies have been proposed and are now 
being developed. These include the identification of predictive or 
prognostic biomarkers for patient selection, and rational design of 
combination therapies of various types. 
For the understanding that the CTLA-4/B7 and PD-1/PD-1L 
mediated T cell inhibitory pathways are through separate and non-
overlapping mechanisms, a concept of combining the CTLA-4 and 
PD-1 blocking agents (ipilimumab, nivolumab) has been tested first 
in patients with advanced melanoma in a clinical trial (Phase I), which 
demonstrated very impressive objective responses in more than 50% 
of patients, most of them with a tumor reduction of 80% or above 
[82]. There are now many ongoing studies testing the combinational 
approaches in other cancer types with preliminary but promising 
results too [23,77]. In this very direction, perhaps we also ought to 
consider the combinational approach in a wider spectrum to embrace 
certain key soluble mediators, such as IL-10 and IDO (indoleamine 
2,3-dioxygenase), potentially involved in the processes [21,83]. PD-L 
signaling has previously been shown to induce the expression of IL-
10, indicating that this immunosuppressive cytokine may serve as 
a down-stream molecule involved in the PD-1-mediated immune 
regulation [84]. In another study, it has also been demonstrated that 
IL-10 and PD-L1 could operate through distinct pathways to suppress 
T-cell activity during persistent viral infection [85]. By targeting these 
molecular switches of multiple types, and through combinations with 
conventional cancer therapies such as chemotherapy, radiotherapy 
and also post-surgical operational therapy, better clinical outcomes 
are now widely anticipated. Another area with great potential is to 
apply the very concept in combination with the vaccination approach, 
to focus more on the antigen-specificity and immunological memory 
too. This together with the possibility to identify Tumor-Specific 
Mutants (TSA) with high immunogenicity through immuno-epitope 
mapping [86], higher impact is now also expected timely upon further 
clinical translation. The ultimate aim is to maximize the clinical 
benefit and, possibly, to find a real cure for cancer in the future. 
Concluding Remarks: Vaccination against Cancers & 
Its Near Future Prospective
In summary and in brief, through a better understanding of the 
cellular and molecular mechanisms underlying autoimmunity versus 
tumor immunity and its regulation, it has greatly advanced our 
knowledge about the complex tumor immune escaping strategies. It 
has also helped to explain why the most effective way to enhance host 
immunity against cancer is by targeting the negative arm of immune 
functions. By applying clinically the Allison’s concept of Immune 
Citation: Huang FP. Therapeutic Vaccination against Cancers- A Conceptual Overview with Updates on the 
Immunological Approach. SM Vaccine Vaccin. 2015;1(2):1009.
Page 5/6
Gr   upSM Copyright  Huang FP
Checkpoint Blockade and beyond, it is now anticipated with high 
optimism that the field of cancer vaccination is to be revolutionized 
and getting a real boost soon.
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